156 related articles for article (PubMed ID: 27307147)
1. Quality and predictors of anticoagulant control with vitamin K antagonist for stroke prevention in atrial fibrillation.
Wilson MR; Parakramawansha R; Quinn TJ; Tait RC
Thromb Haemost; 2016 Aug; 116(3):578-80. PubMed ID: 27307147
[No Abstract] [Full Text] [Related]
2. Stroke prevention in atrial fibrillation.
Freedman B; Potpara TS; Lip GY
Lancet; 2016 Aug; 388(10046):806-17. PubMed ID: 27560276
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
4. Prevention of stroke in patients with atrial fibrillation.
Med Lett Drugs Ther; 2009 Jun; 51(1313):41. PubMed ID: 19478692
[No Abstract] [Full Text] [Related]
5. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
6. Vitamin K antagonist use for all patients with hypertrophic cardiomyopathy and atrial fibrillation: analysis of the literature and guideline review.
Oliphant CS; McCullough J; Hashim T; Khouzam RN
Future Cardiol; 2014 Mar; 10(2):229-33. PubMed ID: 24762250
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulant therapy in atrial fibrillation: vitamin K antagonists or novel oral anticoagulant drugs?
Riva N; Borg Xuereb C; Ageno W
J Cardiovasc Med (Hagerstown); 2015 Feb; 16(2):139-41. PubMed ID: 25539157
[No Abstract] [Full Text] [Related]
8. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
[TBL] [Abstract][Full Text] [Related]
9. Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants.
Turagam MK; Velagapudi P; Flaker GC
Clin Interv Aging; 2015; 10():1431-44. PubMed ID: 26366064
[TBL] [Abstract][Full Text] [Related]
10. Stroke prevention in atrial fibrillation: do we still need warfarin?
Diener HC; Weber R; Lip GY; Hohnloser SH
Curr Opin Neurol; 2012 Feb; 25(1):27-35. PubMed ID: 22143201
[TBL] [Abstract][Full Text] [Related]
11. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.
Renda G; di Nicola M; De Caterina R
Am J Med; 2015 Sep; 128(9):1007-14.e2. PubMed ID: 25910790
[TBL] [Abstract][Full Text] [Related]
12. Gaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation.
Hylek EM; Ko D; Cove CL
Thromb Haemost; 2014 May; 111(5):783-8. PubMed ID: 24573511
[TBL] [Abstract][Full Text] [Related]
13. Clinical practice. Care of patients receiving long-term anticoagulant therapy.
Schulman S
N Engl J Med; 2003 Aug; 349(7):675-83. PubMed ID: 12917305
[No Abstract] [Full Text] [Related]
14. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Senoo K; Lip GY
Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
[TBL] [Abstract][Full Text] [Related]
15. New therapies for stroke prevention in atrial fibrillation: the long road to enhanced efficacy.
Freedman JE; Gersh BJ
Circulation; 2009 Sep; 120(12):1024-6. PubMed ID: 19738132
[No Abstract] [Full Text] [Related]
16. SAME-TT2R 2 score and vitamin K antagonist therapy.
Wiwanitkit V
Intern Emerg Med; 2014 Dec; 9(8):909. PubMed ID: 24908388
[No Abstract] [Full Text] [Related]
17. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
Paikin JS; Haroun MJ; Eikelboom JW
Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
[TBL] [Abstract][Full Text] [Related]
18. Summaries for patients. Rivaroxaban in patients transitioned from vitamin K antagonist therapy.
Ann Intern Med; 2013 Jun; 158(12):I-28. PubMed ID: 23778921
[No Abstract] [Full Text] [Related]
19. Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation.
Liew A; Eikelboom JW; O'Donnell M
Curr Opin Cardiol; 2012 Jul; 27(4):331-9. PubMed ID: 22573171
[TBL] [Abstract][Full Text] [Related]
20. Stroke prevention in atrial fibrillation: another step sideways.
Go AS; Singer DE
Lancet; 2008 Jan; 371(9609):278-80. PubMed ID: 18294981
[No Abstract] [Full Text] [Related]
[Next] [New Search]
